Snapshot A 28-year-old man presents to his primary care physician for fatigue, malaise, and abdominal pain. He reports his symptoms began a few days ago and have progressively worsened. His symptoms are associated with nausea, 2 episodes of emesis, and generalized pruritus. Social history is significant for recent travel to India. He is currently sexually active with multiple men and does not use condoms. Physical examination is notable for scleral icterus, generalized jaundice, and hepatomegaly. Serologic testing is remarkable for anti-HAV IgM antibodies. Introduction Classification a Hepatovirus in the Picornaviridae family single-stranded positive-sense RNA virus with an icosahedral capsid Epidemiology risk factors sexual contact working in a daycare serving in the military eating raw or undercooked shellfish and vegetables Transmission via the fecal-oral route Pathogenesis within the cytoplasm of a hepatocyte, the virus replicates CD8+ T-cells and natural killer cells destroy the infected hepatocytes, leading to hepatocellular damage when the immune response to the infected hepatocytes is severe, it can result in severe hepatitis Prognosis typically a self-limited illness does not become a chronic condition Presentation Symptoms nausea and vomiting anorexia abdominal pain dark urine pale stools Physical exam hepatomegaly jaundice and scleral icterus Studies Serologic testing anti-HAV IgM active infection is present anti-HAV IgG a previous infection was present no active disease the patient is protected against infection elevated aminotransferases Differential Hepatitis B infection differentiating factors presence of anti-hepatitis B antibodies in serological testing Hepatitis C infection differentiating factor presence of anti-hepatitis C antibodies in serological testing Treatment Medical hepatitis A virus (HAV) vaccine indication all children at 1 year of age all children between ages 2 and 18 who live in an area with a high disease incidence people who travel or work in countries with a high disease incidence men who have sex with men illicit drug users patients with chronic liver disease comments used to protect against exposure to the HAV immune globulin indication in infants < 6 months of age in travelers who have a contraindication to the vaccine (e.g., allergy) comments this provides passive immunization against the HAV hepatitis A virus vaccine and immune globulin indication patients with chronic liver disease immunocompromised patients who are not able to mount an adequate immune response to the hepatitis A vaccine Complications Cholestatic hepatitis Fulminant hepatitis (< 1% of cases)
QUESTIONS 1 of 2 1 2 Previous Next Lab Values Blood Hematologic Cerebrospinal Sweat, Urine, and BMI Blood, Plasma, Serum Reference Range ALT 8-20 U/L Amylase, serum 25-125 U/L AST 8-20 U/L Bilirubin, serum (adult) Total // Direct 0.1-1.0 mg/dL // 0.0-0.3 mg/dL Calcium, serum (Ca2+) 8.4-10.2 mg/dL Cholesterol, serum Rec: < 200 mg/dL Cortisol, serum 0800 h: 5-23 μg/dL //1600 h: 3-15 μg/dL 2000 h: ≤ 50% of 0800 h Creatine kinase, serum Male: 25-90 U/LFemale: 10-70 U/L Creatinine, serum 0.6-1.2 mg/dL Electrolytes, serum Sodium (Na+) 136-145 mEq/L Chloride (Cl-) 95-105 mEq/L Potassium (K+) 3.5-5.0 mEq/L Bicarbonate (HCO3-) 22-28 mEq/L Magnesium (Mg2+) 1.5-2.0 mEq/L Estriol, total, serum (in pregnancy) 24-28 wks // 32-36 wks 30-170 ng/mL // 60-280 ng/mL 28-32 wk // 36-40 wks 40-220 ng/mL // 80-350 ng/mL Ferritin, serum Male: 15-200 ng/mLFemale: 12-150 ng/mL Follicle-stimulating hormone, serum/plasma Male: 4-25 mIU/mL Female: premenopause: 4-30 mIU/mL midcycle peak: 10-90 mIU/mL postmenopause: 40-250 pH 7.35-7.45 PCO2 33-45 mmHg PO2 75-105 mmHg Glucose, serum Fasting: 70-110 mg/dL2-h postprandial:<120 mg/dL Growth hormone - arginine stimulation Fasting: <5 ng/mLProvocative stimuli: > 7ng/mL Immunoglobulins, serum IgA 76-390 mg/dL IgE 0-380 IU/mL IgG 650-1500 mg/dL IgM 40-345 mg/dL Iron 50-170 μg/dL Lactate dehydrogenase, serum 45-90 U/L Luteinizing hormone, serum/plasma Male: 6-23 mIU/mL Female: follicular phase: 5-30 mIU/mL midcycle: 75-150 mIU/mL postmenopause 30-200 mIU/mL Osmolality, serum 275-295 mOsmol/kd H2O Parathyroid hormone, serume, N-terminal 230-630 pg/mL Phosphatase (alkaline), serum (p-NPP at 30° C) 20-70 U/L Phosphorus (inorganic), serum 3.0-4.5 mg/dL Prolactin, serum (hPRL) < 20 ng/mL Proteins, serum Total (recumbent) 6.0-7.8 g/dL Albumin 3.5-5.5 g/dL Globulin 2.3-3.5 g/dL Thyroid-stimulating hormone, serum or plasma .5-5.0 μU/mL Thyroidal iodine (123I) uptake 8%-30% of administered dose/24h Thyroxine (T4), serum 5-12 μg/dL Triglycerides, serum 35-160 mg/dL Triiodothyronine (T3), serum (RIA) 115-190 ng/dL Triiodothyronine (T3) resin uptake 25%-35% Urea nitrogen, serum 7-18 mg/dL Uric acid, serum 3.0-8.2 mg/dL Hematologic Reference Range Bleeding time 2-7 minutes Erythrocyte count Male: 4.3-5.9 million/mm3Female: 3.5-5.5 million mm3 Erythrocyte sedimentation rate (Westergren) Male: 0-15 mm/hFemale: 0-20 mm/h Hematocrit Male: 41%-53%Female: 36%-46% Hemoglobin A1c ≤ 6 % Hemoglobin, blood Male: 13.5-17.5 g/dLFemale: 12.0-16.0 g/dL Hemoglobin, plasma 1-4 mg/dL Leukocyte count and differential Leukocyte count 4,500-11,000/mm3 Segmented neutrophils 54%-62% Bands 3%-5% Eosinophils 1%-3% Basophils 0%-0.75% Lymphocytes 25%-33% Monocytes 3%-7% Mean corpuscular hemoglobin 25.4-34.6 pg/cell Mean corpuscular hemoglobin concentration 31%-36% Hb/cell Mean corpuscular volume 80-100 μm3 Partial thromboplastin time (activated) 25-40 seconds Platelet count 150,000-400,000/mm3 Prothrombin time 11-15 seconds Reticulocyte count 0.5%-1.5% of red cells Thrombin time < 2 seconds deviation from control Volume Plasma Male: 25-43 mL/kgFemale: 28-45 mL/kg Red cell Male: 20-36 mL/kgFemale: 19-31 mL/kg Cerebrospinal Fluid Reference Range Cell count 0-5/mm3 Chloride 118-132 mEq/L Gamma globulin 3%-12% total proteins Glucose 40-70 mg/dL Pressure 70-180 mm H2O Proteins, total < 40 mg/dL Sweat Reference Range Chloride 0-35 mmol/L Urine Calcium 100-300 mg/24 h Chloride Varies with intake Creatinine clearance Male: 97-137 mL/minFemale: 88-128 mL/min Estriol, total (in pregnancy) 30 wks 6-18 mg/24 h 35 wks 9-28 mg/24 h 40 wks 13-42 mg/24 h 17-Hydroxycorticosteroids Male: 3.0-10.0 mg/24 hFemale: 2.0-8.0 mg/24 h 17-Ketosteroids, total Male: 8-20 mg/24 hFemale: 6-15 mg/24 h Osmolality 50-1400 mOsmol/kg H2O Oxalate 8-40 μg/mL Potassium Varies with diet Proteins, total < 150 mg/24 h Sodium Varies with diet Uric acid Varies with diet Body Mass Index (BMI) Adult: 19-25 kg/m2 Calculator ( ) xy AC 7 8 9 ÷ 4 5 6 × 1 2 3 - 0 . = + (M1.MC.16) A 35-year-old male comes to clinic with a 1 week history of diarrhea, fatigue, fever, and nausea. He states that he recently returned from a trip to India and that his wife also has similar symptoms. They did not receive any immunizations prior to embarking on this trip. He admits to recent unprotected sexual encounters, frequent alcohol use, and a distant history of IV drug use. Furthermore, he reports receiving a blood transfusion after a motor vehicle accident 5 years ago. On exam, he is noted to have a fever of 101.8 and his eyes are as seen in Figure A. Which of the following risk factors is most likely responsible for his condition? Review Topic QID: 104807 FIGURES: A 1 Unprotected sex 56% (5/9) 2 History of IV drug use 11% (1/9) 3 Recent international travel 33% (3/9) 4 History of blood transfusions 0% (0/9) 5 Alcohol consumption 0% (0/9) M1 Select Answer to see Preferred Response PREFERRED RESPONSE 3 Sorry, this question is for PEAK Premium Subscribers only Upgrade to PEAK